This page is part of the FHIR Specification (v5.0.0-ballot: R5 Ballot - see ballot notes). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B
Biomedical Research and Regulation Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: Not linked to any defined compartments |
This is the narrative for the resource. See also the XML, JSON or Turtle format. This example conforms to the profile MedicinalProductDefinition.
Generated Narrative
Id : equilidem-with-ing-and-auth
Identifier : Equilidem25
Combined Pharmaceutical Dose Form : tablet
Indication : Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Legal Status Of Supply : Prescription only medicine
classification : B01A
Ingredients :
Role : active
substance : Equilidonium Phosphate
- Presentation * 22 ml/1 tablet
Role : excipient
substance : Calcium Carbonate
- Presentation * 3 ml/tablet
- | ProductName |
* | Equilidem 2.5 mg film-coated tablets |
- | Product |
* | Link to generic equivalent |
- | Manufacturer |
* | EquiliDrugCo Processing Inc. |
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.